PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT
2.1 Preface
2.2 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE
• Market ecosystem
• Market characteristics
• Market segmentation analysis
• Pipeline

PART 04: MARKET SIZING
• Market definition
• Market sizing 2018
• Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS
• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition

PART 06: MARKET SEGMENTATION BY TYPE
• Market segmentation by type
• Comparison by type
• Synthetic statins - Market size and forecast 2018-2023
• Natural statins - Market size and forecast 2018-2023
• Market opportunity by type

PART 07: CUSTOMER LANDSCAPE

PART 08: MARKET SEGMENTATION BY APPLICATION
• Dyslipidemia
• Others

PART 09: GEOGRAPHIC LANDSCAPE
• Geographic segmentation
• Geographic comparison
• Americas - Market size and forecast 2018-2023
• EMEA - Market size and forecast 2018-2023
• APAC - Market size and forecast 2018-2023
• Key leading countries
• Market opportunity

PART 10: DECISION FRAMEWORK

PART 11: DRIVERS AND CHALLENGES
• Market drivers
• Market challenges

PART 12: MARKET TRENDS

PART 13: VENDOR LANDSCAPE
• Overview
• Landscape disruption

PART 14: VENDOR ANALYSIS
• Vendors covered
• Vendor classification
• Market positioning of vendors
• AstraZeneca
• Merck
• Novartis
• Pfizer

PART 15: APPENDIX
• Research methodology
• List of abbreviations

PART 16: EXPLORE TECHNAVIO

Exhibit 01: Global CVD treatment market
Exhibit 02: Segments of global CVD treatment market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: List of statins evaluated in late-stage clinical trials
Exhibit 06: Market definition - Inclusions and exclusions checklist
Exhibit 07: Market size 2018
Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 10: Five forces analysis 2018
Exhibit 11: Five forces analysis 2023
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition - Five forces 2018
Exhibit 18: Type - Market share 2018-2023 (%)
Exhibit 19: Comparison by type
Exhibit 20: List of some synthetic statins
Exhibit 21: Synthetic statins - Market size and forecast 2018-2023 ($ millions)
Exhibit 22: Synthetic statins - Year-over-year growth 2019-2023 (%)
Exhibit 23: Examples of natural statins
Exhibit 24: Natural statins - Market size and forecast 2018-2023 ($ millions)
Exhibit 25: Natural statins - Year-over-year growth 2019-2023 (%)
Exhibit 26: Market opportunity by type
Exhibit 27: Customer landscape
Exhibit 28: Market share by geography 2018-2023 (%)
Exhibit 29: Geographic comparison
Exhibit 30: Americas - Market size and forecast 2018-2023 ($ millions)
Exhibit 31: Americas - Year-over-year growth 2019-2023 (%)
Exhibit 32: EMEA - Market size and forecast 2018-2023 ($ millions)
Exhibit 33: EMEA - Year-over-year growth 2019-2023 (%)
Exhibit 34: APAC - Market size and forecast 2018-2023 ($ millions)
Exhibit 35: APAC - Year-over-year growth 2019-2023 (%)
Exhibit 36: Key leading countries
Exhibit 37: Market opportunity
Exhibit 38: Status of generic availability in US
Exhibit 39: Impact of generics on sales of branded products
Exhibit 40: Potential statin-drug interactions
Exhibit 41: Commonly occurring side effects of some statins
Exhibit 42: Impact of drivers and challenges
Exhibit 43: Mobile apps for cholesterol management
Exhibit 44: Vendor landscape
Exhibit 45: Landscape disruption
Exhibit 46: Vendors covered
Exhibit 47: Vendor classification
Exhibit 48: Market positioning of vendors
Exhibit 49: AstraZeneca - Vendor overview
Exhibit 50: AstraZeneca - Business segments
Exhibit 51: AstraZeneca - Organizational developments
Exhibit 52: AstraZeneca - Geographic focus
Exhibit 53: AstraZeneca - Key offerings
Exhibit 54: Merck - Vendor overview
Exhibit 55: Merck - Business segments
Exhibit 56: Merck - Organizational developments
Exhibit 57: Merck - Geographic focus
Exhibit 58: Merck - Segment focus
Exhibit 59: Merck - Key offerings
Exhibit 60: Novartis - Vendor overview
Exhibit 61: Novartis - Business segments
Exhibit 62: Novartis - Organizational developments
Exhibit 63: Novartis - Geographic focus
Exhibit 64: Novartis - Segment focus
Exhibit 65: Novartis - Key offerings
Exhibit 66: Pfizer - Vendor overview
Exhibit 67: Pfizer - Business segments
Exhibit 68: Pfizer - Organizational developments
Exhibit 69: Pfizer - Geographic focus
Exhibit 70: Pfizer - Segment focus
Exhibit 71: Pfizer - Key offerings

Companies Mentioned
• AstraZeneca
• Merck
• Novartis
• Pfizer